Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Debrisoquine oxidation phenotype during neuroleptic monotherapy.

European journal of clinical pharmacology - 1 Jan 1991

Spina E, Martines C, Caputi A P, Cobaleda J, Piñas B, Carrillo J A, Benitez J

Abstract excerpt

The debrisoquine oxidation phenotype was determined in 91 schizophrenic patients on monotherapy with different neuroleptics and in 67 untreated healthy volunteers. The prevalence of poor metabolizers of debrisoquine was significantly higher in the patients (46.2%) than in the healthy subjects (7.5%). Treatment with phenothiazine antipsychotics (chlorpromazine, levomepromazine and thioridazine) was associated with...

Topics

Adult
Aged
Antipsychotic Agents
Cytochrome P-450 Enzyme System
Debrisoquin
Female
Humans
Male
Middle Aged
Oxidation-Reduction
Phenotype
Polymorphism, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Thioridazine

Source

Identifiers

PMID: 1684751
DOI: 10.1007/BF00626371

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-1684751-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Debrisoquine oxidation phenotype during neuroleptic monotherapy.PMID 1684751Read ↗

Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients.Semantic proximity Read ↗

Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.Semantic proximity Read ↗

Debrisoquine 4-hydroxylation and sulphamethazine N-acetylation in patients with schizophrenia and major depression.Semantic proximity Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.Semantic proximity Read ↗

Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions.Semantic proximity Read ↗

Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia.Semantic proximity Read ↗

Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.Semantic proximity Read ↗

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects.Semantic proximity Read ↗

Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.Semantic proximity Read ↗

Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.Semantic proximity Read ↗

Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.